No Prescription |
 |
 | ||
|
ARKAMIN Catapres |
|
| ||
No Prescription » Prescription Drugs 2 » ARKAMIN Catapres This medication is used alone or with other medications to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes heart attacks and kidney problems. Clonidine belongs to a class of drugs (central alpha agonists) that act in the brain to lower blood pressure. It works by relaxing blood vessels so blood can flow more easily.OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.This drug may also be used to treat painful menstrual periods hot flashes that occur with menopause attention deficit hyperactivity disorder (ADHD) and withdrawal symptoms from dependence on narcotics alcohol or nicotine (smoking).How to use Clonidine OralTake this medication by mouth with or without food usually twice daily (in the morning and at bedtime) or as directed by your doctor.The dosage is based on your medical condition and response to treatment.Use this medication regularly to get the most benefit from it. To help you remember take it at the same times each day. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.Do not stop taking this medication without first consulting your doctor. Withdrawal reactions (e.g. nervousness agitation shaking headache) and a rapid rise in blood pressure may occur when the drug is abruptly stopped. The risk is greater if you have used this drug for a long time or in high doses or if you are also taking a beta blocker (e.g. atenolol). There have also been rare reports of severe (possibly fatal) reactions from stopping this drug too quickly (e.g. stroke). Therefore it is important that you do not run out of clonidine or miss any doses. Tell your doctor or pharmacist immediately if you are unable to take the medication (e.g. due to vomiting). If you must stop taking this drug your dose should be gradually decreased over several days as directed by your doctor.When used for a long time this medication may not work as well and may require different dosing or an additional medication. Talk with your doctor if this medication stops working well (e.g. your routine blood pressure readings increase). Buy ARKAMIN Catapres and other Prescription Drugs 2 products online at Medstore. 359
About ARKAMIN Catapres: Product Type: Prescription Drugs 2 ARKAMIN ( Catapres Generic Clonidine ) ARKAMIN (Catapres Generic Clonidine) Catapres Generic Clonidine 100mcg Tabs 30 (3 x 10) Catapres Generic Clonidine ARKAMIN
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
